Neonatal Respiratory Articles & Analysis
2 news found
(NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced ...
With a clinical trial for an aerosolized surfactant therapy recently completed and other product developments underway, ONY Biotech is poised to change the landscape of neonatal respiratory therapy as it’s currently known with the potential for minimally invasive ...